SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Napro Biotherap(npro)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: trevor john wilkinson who started this subject11/3/2003 12:47:41 PM
From: John McCarthy   of 478
 
2003 - Investor Presentation - drug canidates

secfilings.nasdaq.com

NBT 287 In Vitro Data

50% Inhibitory Concentration in Human Tumor Cell Lines
Human Tumor Cell Lines
NBT 287
ug/ml/hr

Paclitaxel
ug/ml/hr

MDR-1

Small Cell Lung Cancer: SHP-77

0.02

04.0

Expressing
Cell Lines
Breast Cancer: NCI-AR
0.25
40.0
Mutant Tubulin
Ovarian Cancer: IA9ptx10
0.10
5.0
Cell Line


Up to ~200x more potent than paclitaxel in resistant cell lines

John McCarthy
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News